Esketamine Combined With PRF of DRG for Postherpetic Neuralgia
ConditionPostherpetic Neuralgia
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBeijing Tiantan Hospital
About this trial
This trial's primary objective is to compare the analgesic efficacy of esketamine in combination with pulsed radiofrequency (PRF) of dorsal root ganglion(DRG) against that of PRF monotherapy in patients with postherpetic neuralgia(PHN).
Eligibility criteria
Qualifiers
Ages more than 18 years;
Pain persisting for over three months following the onset of the herpes zoster skin rash;
Lesions located in in the unilateral cervical, thoracic, and lumbosacral segments;
Having an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10= worst possible pain)； Planned to perform CT-guided PRF treatment of the Dorsal root ganglion（DRG）
Disqualifiers
Obstructive sleep apnoea syndrome;
Those who receive other more invasive treatments, such as radiofrequency thermocoagulation (RFT) of DRG.
A history of systemic immune diseases, organ transplantation, or cancers;
A history of severe cardiopulmonary, hepatic, renal dysfunction or coagulation function disorder;
Trial design
Treatments tested in this trial
- esketamine+PRF treatment group
- PRF treatment group
Treatment groups
186 Participants
are divided into 2 treatment groupsSponsors and collaborators
Beijing Tiantan Hospital
Lead sponsor
Beijing Xiaotangshan Hospital
Collaborator
The First Hospital of Fangshan District,Beijing
Collaborator
Beijing Ditan Hospital
Collaborator
Hengshui People's Hospital
Collaborator
Source ClinicalTrials.gov